GLP1_NEW
TERN-601 750 mg tablet once daily
TERN60_PO_750MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 6.94 (0.48 to 134) | 0.17 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.30 (0.90 to 25.30) | 0.29 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.68 (2.84 to 25.12) | 0.20 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 14.54 (2.91 to 103) | 0.16 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.45 (0.04 to 3.26) | 0.85 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.78 (0.50 to 19.58) | 0.39 |